Management Team

Successful track record of developing and commercializing innovative and clinically significant healthcare technologies.


Scott Schorer

President and Chief Executive Officer

Scott brings over 20 years of executive experience in the medical device industry, having both founded and helmed numerous companies in the healthcare space.

After graduating from Dartmouth College with Bachelor of Arts and Bachelor of Engineering degrees, Scott began his career as an infantry officer in the 82nd Airborne Division.

Following his military service, he began his medical device career as a sales representative for a surgical distributor. After identifying a need in the healthcare supply chain space, he co-founded and led CentriMed before the company was acquired by Global Healthcare Exchange. Scott next founded and led Innovative Spinal Technologies for eight years before the company was sold. He led the $100m Americas geography of Systagenix, a private equity acquisition of the J&J Advanced Wound Care Division.

More recently, Scott has served as a president and consultant to numerous boards and CEOs across a wide variety of companies in the medical device, biologics and related markets. He has raised over $120m in public and private equity investments and also the co-inventor of six patents.


Brian Callahan

Chief Compliance Officer, Executive Vice President of Clinical, Regulatory, and Quality Affairs

Brian is an accomplished senior compliance executive with more than 25 years of experience in the medical device, pharmaceutical and biologics industries.

He began his career in the United States Army as a nuclear weapons specialist and has experience working for Johnson & Johnson, Covidien and Quintiles.

In 2002, Brian founded EEC & Associates, a global compliance consulting company providing clinical, regulatory and quality services to domestic and international life science companies. More recently, Brian was Executive Vice President of Clinical, Quality and Regulatory Affairs at Histogenics Corporation and was instrumental in raising $49 million to restart the NeoCart Pivotal Phase III study.

Houry Youssoufian

Vice President of Finance and Accounting

Houry is an accomplished senior finance executive with more than 20 years of experience in publicly and privately traded, high-growth and transition stage companies mainly focused in the life science sector. She has her MBA from Simmons College Graduate School of Management and earned her CPA while working at Price Waterhouse Coopers.

Prior to joining GI Dynamics, she served as a consultant to various biotechnology companies including Sage Therapeutics, Voyager Therapeutics and Infinity Pharmaceutical. Houry has been Vice President of Finance at Immunetics, Inc., and Site Head of Finance at Novartis Institute of Biomedical Research Inc.